Keynote 8

"Defeating dementia for people with Down syndrome and others with intellectual and developmental disabilities – A matter of Health Equity"

Hampus Hillerstrom

Hampus Hillerstrom became president and CEO in 2017, after serving on the board of directors for three years. Previously, he co‐founded Proclara Biosciences in 2007, a company developing a novel approach for treating Alzheimer’s, Parkinson’s, and other protein misfolding diseases. Previously, he spent three years as an associate at leading European biotech venture capital firm HealthCap where he participated in a large number of investment transactions including several IPOs. Since 2007, Hampus has co-founded three biotech companies in neuroscience and in eye conditions. Hampus also spearheaded a project at AstraZeneca to evaluate decision‐making leading to Phase III clinical trials and worked on the pharmaceutical industry at investment bank Lazard. Hampus holds a master’s in economics and finance from the University of St. Gallen (Switzerland), an MBA from Harvard Business School, and an MSc in Health Sciences and Technology from MIT/Harvard Medical School (HST). Hampus and his wife, Lianor are raising sons Oskar, who has Down Syndrome, and Sebastian. In addition to his focus on research, Hampus and Lianor are big proponents in their community for early intervention therapies and meaningful inclusion in school.